Abstract: A method is provided for heating an electrically conductive fluid, including steps of: (i) circulating the fluid in a circuit from an inlet to an outlet, through an inlet path of the circuit in which the fluid flows in a first average direction and an outlet path of the circuit in which the fluid flows in a second average direction substantially opposite to the first direction; (ii) subjecting the fluid to a specific ohmic heating while the fluid flows through the outlet path; and (iii) transferring heat from the fluid flowing through the outlet path to the fluid flowing through the inlet path by thermal conduction through an at least partially first electrically insulated partition wall. An associated heating device is also provided.

Abstract: A method is provided for manufacturing near-field optical probes including at least one organo-mineral material with an organic part and a mineral part, the method including steps of irradiating at least partially the organo-mineral material with a radiation beam to polymerize the organic part in the irradiated areas, and polycondensing the mineral part by sol-gel process. Also disclosed are near-field optical probes and AFM and SNOM systems using the probes.

Abstract: The invention relates to fragments of the DAXX and FADD proteins that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis.

Abstract: The purpose of the present invention is to improve the efficiency of conversion between terahertz electromagnetic wave energy and direct current energy via plasma waves in a terahertz electromagnetic wave conversion device with a field effect transistor structure. This invention has an HEMT structure having a substrate, an electron transit layer, an electron supply layer, a source and a drain, and includes a first and second group of gates. The gate length of each finger of the first group of gates is narrower than the gate length of each finger of the second group of gates, and each finger of each group of gates is disposed between the source and the drain on the same cycle. A first and second distance from each finger of the first group of gates to two fingers of the second group of gates adjacent to each finger are unequal lengths.

Abstract: The present invention relates to compound (I) for use as an agent for preventing, inhibiting or treating AIDS, wherein X is CR0 or N; R0, R1, R2, R3, R4, R7 and R8 independently represent a hydrogen atom, a halogen atom or a group chosen among a (C1-C5)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)fluoroalkyl group, a (C1-C5)alkoxy group, a (C1-C5)fluoroalkoxy group, a —CN group, a —COORa group, a —NO2 group, a —NRaRb group, a —NRa—SO2—NRaRb group, a —NRa—SO2—Ra group, a —NRa—C(?O)—Ra group, a —NRa—C(?O)—NRaRb group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group, a —O—P(?O)—(ORc)(ORd) group, a —O—CH2—COORc group and can further be a group chosen among: R5 represents a hydrogen atom, a (C1-C5)alkyl group or a (C3-C6)cycloalkyl group; R10 is a hydrogen atom or a chlorine atom, and R11 is a hydrogen atom or a (C1-C4)alkyl group or anyone of its pharmaceutically acceptable salts.

Abstract: A method for the diagnosis and/or prognosis of inflammatory states, and the use of at least one soluble receptor-binding (RBD), for the identification and quantication of the expression of membrane receptors present on the surface of target granulocytes, said identification and quantification taking place at a given time or during a given time interval, and allowing the diagnosis and/or prognosis of inflammatory states in a mammal.

Abstract: The invention relates to a method for the chemical synthesis of RNA, comprising the following steps: a) bonding to a solid support of a monomer having formula (II) in which—X1 is a dimethoxytrityl group,—X6 is H or an OAc group or OX3, in which X3 is a group having formula (A), in which X is O or S, R? is H or CH3 and R is selected from a linear or branched alkyl group at C1 to C4 and a R1—O—R2 group in which R1 is an alkyl group at C1 to C2 and R2 is a CH3 group or CH2CH2—O—CH3 or aryl; b) assembly with the monomer having formula (II) bound to the support thereof obtained in step (a) of at least one monomer having formula (III) in which X1, Bp, X3 are as defined for formula (II) and X5 is a hydrogen phosphonate monoester or phosphoramidite group, preferably a 2-cyanoethyl-N,N-diisopropylphosphoramidite group, which is used to obtain a protected single-strand RNA bound to a support.

Abstract: The present invention relates to at least one protein belonging to the bHLH family and/or at least a nucleic acid molecule coding for the bHLH proteins as drug.

Abstract: A method for the identification and quantification of the expression of membrane receptors present on the surface of target cells using at least two soluble receptor binding ligands derived from the soluble part of the glycoprotein of an enveloped virus that interacts with a cellular cognate receptor, the receptor binding ligand containing a part or the totality of one of the receptor binding domains (RBD) of the glycoprotein, and the soluble receptor binding ligand being liable to interact with the at least one membrane receptor of a target cell, for the identification and quantification of the expression of membrane receptors present on the surface of target cells, the identification and quantification taking place at a given time or during a given time interval, and allowing the determination of a physiological state of the target cell.

Abstract: The invention relates to a polymer comprising at least one polymeric chain of a first type, the said chain comprising at least two blocks, the same or different, the said blocks comprising repeat units derived from the polymerisation of styrene monomers, the said units comprising at least one phenyl pendant group carrying at least one —SO3R group, R possibly being a hydrogen atom, an alkyl group or cationic counter-ion, the said two blocks being separated by a spacer group, the spacer group is a perfluorocarbon group.

Abstract: The invention relates to a static converter connected between an electrical voltage source (4) and an electrical load (6), said converter including a main static conversion arm (16) comprising an output electronic switching cell and a backup conversion arm (18) having identical structures. The static converter includes a pair of fuses (70, 72) connected on either side of the main arm (16), and a switching circuit (26) comprising a connection element (80) connecting the backup arm (18) to the connection points between the fuses and the input terminals of the main arm, such that, when a fault occurs on one of the switching cells forming the main arm (16), a stable conductive link is established between the two fuses (70, 72), the main arm (16) is isolated by the two fuses (70, 72), and the backup arm (18) is spontaneously connected to the output of the main arm (18) via the conductive line and replaces the main arm.

Abstract: An active material for a lithium battery electrode comprises a phase having the formula Li2+v?4cCcTi3?wFexMyM?zO7??, in which M and M? are metal ions of groups of 2 to 15 having an ionic radius between 0.5 and 0.8 ? in an octahedral environment, v, w, x, y, z and ? being associated by the relationships: 2?=?v+4w?3x?ny?n?z, with n and n? being the respective formal degrees of oxidation of M and M?; ?0.5?v?0.5; y+z>0; x+y+z=w; and 0<w?0.3; and wherein at least part of the lithium is substituted by carbon according to the relationship 0<c(2+v)/4. The invention also includes a method for synthesizing the active material which comprises mixing and grinding the precursor compounds containing the metal components, carbon and oxygen; heating the mixture in an inert atmosphere at a temperature of 950 to 1050° C. in order to make a ceramic phase; and rapidly cooling the ceramic phase to produce the active material.

Abstract: The present invention concerns a method for treating and/or preventing a disease in a subject comprising the step of administrating an effective amount of a compound of formula I to a subject in need thereof.

Abstract: The invention relates to a method for functionalizing natural fatty substances: According to said method, plant oils including at least two unsaturations and the derivatives thereof, fatty acids including at least one unsaturated compound and the derivatives thereof, and mixtures of same, are reacted with a thiol derivative of formula (I), at a temperature of between 0° C. and the temperature of total degradation of the natural fatty substance and in the presence of a thermal initiator compound or a redox initiator, or by UV radiation, or by UV radiation and in the presence of a photoinitiator. The invention also relates to the resulting functionalized fatty substances and to the use thereof for the preparation of polymers. The invention further relates to a method for preparing polymers from at least one functionalized fatty substance obtained by said functionalization method.

Abstract: A control device implantable in a human body—includes a control unit and at least one electrode, said control unit being connected to each electrode to control stimulation and/or measurement thereof. The control unit includes: a timing dock; a memory storing configuration data defined to enable configuration of each electrode correlated with identifiers; a memory storing program data describing a time profile correlated with identifiers; an executor activatable to send each electrode electric pulses corresponding to a predetermined program according to a predetermined electrode configuration, according to the clock; a sequencer arranged to receive an ordered plurality of pairs, each including an electrode configuration identifier and a program identifier, and selectively to activate the executor with the electrode and program configuration pairs denoted by the pairs of identifiers received as an input, according to the order thereof and the clock.

Abstract: Nanovectors are disclosed that make it possible to simultaneously target, image, and treat cancerous cells using photodynamic therapy. Also disclosed are novel molecules (I) derived from porphyrins, silica-based nanoparticles comprising the same, and their use in photodynamic therapy.

Abstract: The invention relates to compounds of formula (I) wherein the groups A and B represent independently from each other —CH?CH—, or —C?C—, the terms t, u, v, w represent, independently from each other, values ranging from 0 to 9, the groups Y1 and Y2 can represent independently from each other an alkyl group (linear, branched or substituted) carrying from 1 to 9 carbon atoms, the groups Z1, Z2, Z3, and Z4 can represent independently from each other a chemically reactive group W, such as OH, NH2, SH, the groups Z5 and Z6 represent independently from each other a hydrogen atom, silica nanoparticles functionalized by these compounds, and their use as drugs.

Abstract: The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a —NRiR2 group, a (C1-C4)alkoxy group, a phenoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n? is 1 or 2, R? is a hydrogen atom, a halogen atom or a group chosen among a (Ci-C3)alkyl group, a hydroxyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a (C1-C4)alkoxy group and a —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging.

Abstract: The present invention provides a chimeric polypeptide comprising a plurality of polypeptide domains that are capable of being secreted in combination with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and polynucleotides coding for these polypeptides, for the production of immunogenic compositions based on exosomes or DNA, to screen protein interactions. The present invention also concerns exploiting the properties of exosomes comprising a polypeptide of the invention and immunogenic compositions of the invention in immunology. The present invention concerns the use of exosomes comprising a polypeptide of the invention as a diagnostic tool.

Abstract: The use of metal-accumulating plants for implementing chemical reactions.